Introduction {#s1}
============

Colchicine is a tricyclic alkaloid known for their effects over cytoskeleton, acting as a microtubule depolymerizing agent ([@B19]). Colchicine has been used in a variety of illnesses, including rheumatic and cardiovascular diseases ([@B6]; [@B19]). By changing cytoskeleton dynamics through microtubule disruption, colchicine affects cellular processes including neutrophil extravasation, cytokine secretion among others events associated with inflammation ([@B9]). Based on these properties, it has been approved by the FDA for the treatment of inflammatory diseases in 2009 ([@B7]).

Several electrophysiological studies have shown that colchicine modulates neurotransmission and the function of pentameric ligand-gated ion channels (pLGICs) by altering the microtubule organization ([@B23]; [@B21]; [@B24]; [@B22]). For example, alteration of microtubule stability by colchicine selectively impaired the function of the synaptic and extrasynaptic glycine receptors (GlyRs) in spinal neurons ([@B21]; [@B22]) and reduced the function and allosteric modulation of the *γ*-aminobutyric acid receptor type A (GABA~A~Rs) ([@B23]; [@B24]). Nonetheless, several works have reported the direct effects of colchicine on the function of inhibitory and excitatory pLGICs. Electrophysiological experiments performed in *Xenopus* oocytes have shown that colchicine acts as a competitive antagonist of GlyRs ([@B16]) and of GABA~A~Rs ([@B5]). The inhibition of the glycine and GABA-activated currents was observed instantly and was concentration-dependent. Since the depolymerization of microtubules with colchicine takes at least 1.5 h to reach equilibrium at 30°C ([@B18]), the inhibitory actions of colchicine on GlyRs and GABA~A~Rs were proposed to be independent of microtubule alterations. In addition, the effects of colchicine on GABA responses required no pre-incubation with colchicine ([@B23]), and pre-incubation with the drug failed to enhanced its effect on GlyRs ([@B16]). Moreover, other microtubule-depolarizing agents failed to have similar effects over the ion channel function ([@B16]). On the other hand, further reports have shown that colchicine is able to modulate the 5-Hydroxytryptamine 3A receptor (5-HT~3A~R). Similar to GlyRs and GABA~A~Rs, the colchicine inhibition of 5-HT~3A~R function occurred in the absence of pre-incubation through microtubule-independent mechanisms ([@B10]).

Using biochemical techniques, a recent report has demonstrated that colchicine is able to bind homo-pentameric *α* ~3~GlyRs ([@B26]). This report is particularly interesting because colchicine is an effective treatment for the inflammatory pain in gout flares ([@B9]). On the other hand, recent reports have shown that positive allosteric modulators of *α* ~3~-containing GlyRs displayed analgesic effects in behavioral models of chronic pain ([@B1]; [@B25]). These pieces of evidence suggest that colchicine may exert part of its therapeutic effects through the modulation of *α* ~3~GlyRs. However, the effects of colchicine in the function of *α* ~3~-containing GlyRs are still unknown. In this work, we combine *in silico* docking assays and electrophysiological recordings to evaluate the effects of colchicine in the function of homo-pentameric *α* ~3~GlyRs.

Material and Methods {#s2}
====================

Cell Culture and Transfection {#s2_1}
-----------------------------

HEK 293 cells (CRL-1573; American Type Culture Collection, Manassas, VA, USA) were cultured using standard methods ([@B15]). The cells were transfected using XfectTM Transfection Reagent (Clontech, USA) using 1.0 μg of cDNA plasmid encoding the rat GlyR *α* ~3~ subunit. Cell were co-transfected with a plasmid encoding EGFP (0.5 μg) to identify the transfected cells ([@B15]). All recordings were made 24--36 h after transfection.

Electrophysiology {#s2_2}
-----------------

Glycine-evoked currents were recorded from EGFP-positive transfected HEK 293 cells in the whole-cell voltage-clamp configuration at room temperature (20--24°C) at a holding potential of −60 mV ([@B15]). Patch electrodes (3--4 mΩ) were pulled from borosilicate glass and were filled with (in mM): 120 CsCl, 8 EGTA, 10 HEPES (pH 7.4), 4 MgCl~2~, 0.5 GTP, and 2 ATP. The external solution contained (in mM) 140 NaCl, 5.4 KCl, 2.0 CaCl~2~, 1.0 MgCl~2~, 10 HEPES (pH 7.4), and 10 glucose. Whole-cell recordings were performed with an Axoclamp 200B amplifier (Molecular Devices, USA) and acquired using Clampex 10.1 or Axopatch 10.0 software. Data analysis was performed off-line using Clampfit 10.1 (Axon Instruments, Sunnyvale, CA, USA). Exogenous glycine-evoked currents were obtained using a manually applied pulse (3--4 s) of the agonist and an outlet tube (200 μm ID) of a custom-designed gravity-fed microperfusion system positioned 50--100 μm from the recorded cell. The methodologies employed for the single channel recordings of *α* ~3~GlyRs in the cell-attached configuration have been previously published ([@B17]; [@B15]). The patch pipettes had tip resistances of 10--20 mΩ and were manually fire polished in a microforge (Narishige, Japan). The data were filtered (1-kHz low-pass 8-pole Butterworth) and acquired at 5--20 kHz using an Axopatch 200B amplifier and a 1322A Digidata (Axon Instruments, Union City, CA). Data was acquired using pClamp software and analyzed off-line with Clampfit 10.1 (Axon Instruments, Union City, CA). Colchicine stock was prepared in high purity distilled water and subsequently diluted into the recording solution on the day of the experiment. In whole-cell experiments colchicine was co-applied with glycine using a manually applied pulse (1--2 s). In cell-attached recordings, colchicine was applied to the intra-pipette solution together with glycine. Colchicine was obtained from AK Science (CA, USA). All other reagents were from Sigma-Aldrich (St. Louis, MO, USA).

Molecular Docking Simulations {#s2_3}
-----------------------------

Protein-ligand docking was performed using the structures of *α* ~3~GlyRs in open/closed conformations from the Protein DataBank (PDB ID:5CFB, 5TIO) ([@B12]; [@B13]). The structures of colchicine, strychnine, and glycine were obtained from the PubChem database (CID: 26719, 441071, 750) and prepared using LigPrep (Schrödinger, LLC, New York, NY, 2016) before docking simulations ([@B14]). Initially, free docking protein-ligands were performed using Autodock Vina ([@B20]) in which the extracelullar domain (ECD) of the *α* ~3~GlyRs was used as the protein target. The generated complexes were ranked based on the affinity constants calculated by the same program. Subsequently, site-directed docking was created with Glide (Schrödinger, LLC, New York, NY, 2016) using a receptor grid centered on the amino acids that form the binding site defined in the previous step and an extra-precision (XP) configuration. Analysis of the interface GlyR-molecules included structural and energetic parameters performed by the same software. Additionally, a theoretical ΔG bind was calculated by an energy calculation MM-GBSA using Prime (Schrödinger, LLC, New York, NY, 2016). All images were created using PyMol (version 1.5, DeLano Scientific LLC).

Data Analysis {#s2_4}
-------------

All values were expressed as mean ± s.e.m. of normalized agonist-activated currents. P \< 0.05 was considered statistically significant. For statistical analyses, at least six cells were analyzed per condition. All the statistical analyses and plots were performed with MicroCal Origin 8.0 (Northampton, MA, USA).

Results {#s3}
=======

To test the hypothesis that colchicine modulates directly the function of GlyRs, concentration response curves were generated from HEK293 expressing *α* ~3~GlyRs. All these experiments were performed in the absence of any pre-incubation with colchicine. The co-application of colchicine produced a rapid inhibition of glycine-activated currents (tested at an EC~10--15~ concentration; 30--50 μM). The alkaloid exerted inhibitory effects in concentrations ranging from 1 to 200 μM ([**Figure 1A**](#f1){ref-type="fig"}). The concentration producing the 50% inhibition (IC~50~) was 24 ± 7 μM, with a maximal inhibition of 39 ± 2% at 200 μM (n = 8). Interestingly, the colchicine potency observed in the *α* ~3~GlyRs was not different from the IC~50~ obtained in the *α* ~1~GlyRs (25 ± 6 μM, [**Supplementary Figure S1**](#SF1){ref-type="supplementary-material"}). To obtain additional insights on the nature of this inhibition, glycine concentration--response curves were generated in the absence or presence of 100 μM of colchicine ([**Figure 1B**](#f1){ref-type="fig"}). A right-shift in the glycine concentration curve was observed in presence of colchicine, changing the apparent affinity from 56 ± 4 μM to 253 ± 29 μM (n = 8; p \< 0.01). An estimated K~i~ value of 15 ± 3 μM in the presence of 200 μM of colchicine was calculated using the Cheng--Prusoff equation ([@B8]). To investigate further the mechanisms underlying the ion channel modulation by colchicine, we performed single-channel recordings in the cell-attached configuration ([**Figures 1C, D**](#f1){ref-type="fig"}). No spontaneous activity was observed when patches were perfused with glycine-free solution (\>1 min). However, glycine 100 μM triggered clusters of active periods ([**Figure 1C**](#f1){ref-type="fig"}). The mean current amplitude at +60 mV calculated from the amplitude histogram was 5.5 ± 0.08 pA. The main single conductance (92 ± 2 pS) was determined by current--voltage relationship over a range of voltages from −80 mV to +80 mV as an average from three to five patches ([**Figure 1D**](#f1){ref-type="fig"}). The application of colchicine (100 μM) to membrane patches obtained in the same control cells did not change the main current amplitude (5.4 ± 0.06 pA) and main conductance (91 ± 2 pS (n = 6; p = 0.66). In agreement with our data obtained from whole-cell experiments, colchicine significantly reduced the normalized open probability (nPo) by 47.3% (0.11 ± 0.09 in control conditions *v/s* 0.056 ± 0.04 in colchicine conditions (p \< 0.01, paired t-test). Altogether, these results support a direct inhibition of the channel function by colchicine. Moreover, these data are consistent with a competitive antagonism of colchicine on the *α* ~3~GlyRs.

![Functional modulation of *α* ~3~GlyRs by colchicine. **(A)** The panel shows typical whole-cell current traces recorded in HEK293 cells expressing *α* ~3~GlyRs activated by glycine 30 μM before and during the application of colchicine (Col) (10, 50, 100, and 200 μM). The graph summarizes the percentage of inhibition of the glycine-evoked currents in a concentration-response fashion. **(B)** The panel shows current traces recorded in HEK293 cells expressing *α* ~3~GlyRs activated by glycine (1--1,000 μM) in the absence (left) or presence (right) of colchicine (Col 100 μM). The plot summarizes the glycine concentration-response curve obtained in the absence (black circles) or presence (white circles) of colchicine (100 μM). **(C)** Single-channel activity recorded in cell-attached configuration from cells expressing *α* ~3~GlyR before and in the presence of 100 μM of colchicine. **(D)** The graphs show that colchicine did not modified the main unitary conductance but significantly decreased the open probability (nPo) of the *α* ~3~GlyRs (\*\*\*P \< 0.001, paired Student t-Test).](fphar-11-01143-g001){#f1}

We next performed *in silico* analysis of the interaction of *α* ~3~GlyRs with colchicine using the crystal structure of *α* ~3~GlyRs (PDB: 5CFB) as a template ([**Figure 2**](#f2){ref-type="fig"}). We first performed a free docking protein-ligand using the ECD of *α* ~3~GlyRs as a target region. Under this condition, colchicine showed a preference for the closed state of the *α* ~3~GlyR, generating a series of complexes centered at the orthosteric binding site with slight differences between the orientations of the molecule ([**Figure 2A**](#f2){ref-type="fig"}). We next restricted the docking analyses to the orthosteric site. The analyses revealed that colchicine binds to the closed state of *α* ~3~GlyRs ([**Figure 2B**](#f2){ref-type="fig"}), reaching a docking score of −5.05 and a predicted ΔG bind of −39.48 kcal/mol. The values were in the range to those showed by glycine and strychnine, suggesting a functional interaction ([**Figure 2C**](#f2){ref-type="fig"}). The *α* ~3~GlyRs--colchicine interface showed the formation of two H-bonds from amino acids Q177 (+) and T204 (−), together with a π-cation interaction with R65 (+) that contributes to the stabilization of the complex ([**Supplementary Figure S2**](#SF2){ref-type="supplementary-material"}). No *α* ~3~GlyRs--colchicine complexes were observed when the open conformation of *α* ~3~GlyRs was tested. Thus, our *in silico* studies match well with the functional data obtained in our electrophysiological recordings, suggesting that colchicine modulate the *α* ~3~GlyRs function by direct binding to the orthosteric site, in a competitive manner.

![Binding prediction of colchicine on the *α* ~3~GlyR structure. **(A)** Representative interaction modes of the free docking between the ECD of *α* ~3~GlyR and colchicine. All chains are identical and were colored in cyan and yellow to facilitate the identification of intersubunit regions. **(B)** Binding of colchicine to the orthosteric site of *α* ~3~GlyR predicted by Glide. For comparison, the binding of strychnine is also shown. **(C)** The graphs present the docking scores and the theoretical ΔG bind of interaction of colchicine and strychnine with *α* ~3~GlyRs in the closed state. The value obtained from the docking with glycine under similar conditions has been added as reference.](fphar-11-01143-g002){#f2}

Discussion {#s4}
==========

Colchicine has been used for many years as a therapeutic agent. Its uses also include undesired effects, such as gastrointestinal disturbances and neutropenia. Traditionally, the mechanism by which colchicine affects the cell function has been linked to the inhibition of microtubule polymerization. Since the cytoskeleton controls many aspects of the cell physiology, such as migration and intracellular signaling, the capacity of colchicine as an anti-inflammatory agent has been associated with this specific action ([@B3]). Nevertheless, other studies have shown that colchicine exerts direct actions on ion channels, including GlyRs composed of *α*1 and *α*2 ([@B5]; [@B16]; [@B10]). Interestingly, using a biochemical approach, a recent report demonstrated that colchicine in complex with biotin binds directly to *α* ~3~GlyRs ([@B26]). The authors thus proposed that the colchicine--*α* ~3~GlyRs interaction may explain the mitigating effects of colchicine on inflammatory pain, especially the one caused by the deposition of monosodium urate crystal in gouty arthritis disease. Interestingly, these pieces of evidence are in line with experimental data showing the relevance of the *α* ~3~GlyRs on chronic pain of inflammatory origin and the ability of positive allosteric modulators to exert analgesic effects in behavioral models of chronic pain ([@B2]; [@B11]; [@B1]; [@B25]). However, the effects of colchicine on the *α* ~3~GlyRs function were not described. The present work characterized the *α* ~3~GlyRs--colchicine functional interaction by electrophysiology and bioinformatics. Our electrophysiological studies show that the function of the *α* ~3~GlyRs is inhibited by colchicine at micromolar range (1--200 μM). The glycine-activated current inhibition was not significantly different to those obtained using *α* ~1~GlyRs, in which colchicine was described as a competitive antagonist in a previous study ([@B16]). Single-channel analysis showed that colchicine reduced the ion channel open probability without changes in the conductance. Moreover, molecular modeling and *in silico* docking simulations based on the crystal structure of *α* ~3~GlyRs ([@B13]) showed a favorable binding of colchicine to the orthosteric site. Interestingly, colchicine has a higher preference for the orthosteric site in the closed conformation. However, since our data suggest that colchicine is a competitive antagonist of the *α* ~3~GlyRs, our results suggest that the analgesic effects of colchicine in inflammatory pain are possibly not linked to an enhanced *α* ~3~GlyRs activity. In addition, the comparison between the plasmatic concentrations of colchicine from patients (0.6--9.5 ng/ml) ([@B4]) and the concentrations required to inhibit the GlyR function reported here makes it difficult to suggest that the modulation of GlyRs is a relevant colchicine target in humans.

Conclusion {#s5}
==========

The present work defines the modulatory effects of colchicine on homomeric *α* ~3~GlyRs. Our results provide novel functional information regarding the direct interaction of colchicine with GlyRs, suggesting a molecular mechanism associated with a competitive inhibition at the orthosteric site. Although our experiments does not rule out a possible relevance of *α* ~3~GlyRs on the analgesic actions of colchicine in inflammatory pain (especially in the context of gouty arthritis), our results at least confirm that GlyRs are targets of the alkaloid colchicine at the functional level. Further behavioral and functional experiments are necessary to clarify whether the effects of colchicine on GlyRs are relevant players on the beneficial effects of the alkaloid in inflammatory pain conditions.
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Functional modulation of *α* ~1~GlyRs by colchicine. **(A)** The panel shows typical whole-cell current traces recorded in HEK293 cells expressing *α*1GlyRs activated by glycine 20 μM before and during the application of colchicine (Col) (10, 50, 100, and 200 μM). **(B)** The graph summarizes the percentage of inhibition of the glycine-evoked currents in a dose--response fashion (IC~50~ = 25 ± 6 μM, n = 6).
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###### 

Ligand interaction diagrams of colchicine with the ECD of *α* ~3~GlyRs. Schematic representation of the amino acids involved in the binding of colchicine with the ECD of *α* ~3~GlyR in closed-state conformation. All interactions detected in the *α* ~3~GlyR-colchicine interface are located in the inner box with a cutoff of 4 Å from the receptor. In the two H-bonds formed, T204 and Q177 act as hydrogen-bond donors. For its part, R65 interacts with an aromatic ring of colchicine, an electron-rich π group, to create a pi--cation interaction. The analysis was performed using Maestro (Schrödinger, LLC, NY, 2018).
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